• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    ROTH Capital initiated coverage on Monopar Therapeutics with a new price target

    1/28/21 6:42:55 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNPR alert in real time by email
    ROTH Capital initiated coverage of Monopar Therapeutics with a rating of Buy and set a new price target of $49.00
    Get the next $MNPR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MNPR

    DatePrice TargetRatingAnalyst
    6/23/2025$60.00Buy
    Chardan Capital Markets
    3/19/2025$76.00Overweight
    Piper Sandler
    1/10/2025$72.00Overweight
    Piper Sandler
    10/11/2024$50.00Buy
    Rodman & Renshaw
    11/1/2021$9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $MNPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Robinson Chandler converted options into 13,344 shares and covered exercise/tax liability with 5,865 shares, increasing direct ownership by 11% to 73,472 units (SEC Form 4)

      4 - Monopar Therapeutics (0001645469) (Issuer)

      7/2/25 4:25:14 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Cittadine Andrew converted options into 6,863 shares and covered exercise/tax liability with 2,990 shares, increasing direct ownership by 9% to 45,858 units (SEC Form 4)

      4 - Monopar Therapeutics (0001645469) (Issuer)

      7/2/25 4:24:13 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Tactic Pharma Llc sold $1,166,690 worth of shares (33,334 units at $35.00) (SEC Form 4)

      4 - Monopar Therapeutics (0001645469) (Issuer)

      4/4/25 7:27:32 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Monopar Therapeutics with a new price target

      Chardan Capital Markets initiated coverage of Monopar Therapeutics with a rating of Buy and set a new price target of $60.00

      6/23/25 8:07:37 AM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler resumed coverage on Monopar Therapeutics with a new price target

      Piper Sandler resumed coverage of Monopar Therapeutics with a rating of Overweight and set a new price target of $76.00

      3/19/25 8:17:26 AM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Monopar Therapeutics with a new price target

      Piper Sandler initiated coverage of Monopar Therapeutics with a rating of Overweight and set a new price target of $72.00

      1/10/25 8:29:30 AM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care